12 results on '"Enver Keleszade"'
Search Results
2. Impact of lignans in oilseed mix on gut microbiome composition and enterolignan production in younger healthy and premenopausal women: an in vitro pilot study
- Author
-
Giulia Corona, Anna Kreimes, Monica Barone, Silvia Turroni, Patrizia Brigidi, Enver Keleszade, and Adele Costabile
- Subjects
Flaxseed ,Enterolignans ,Enterolactone ,Enterodiol ,Gut microbiome ,Metabolism ,Microbiology ,QR1-502 - Abstract
Abstract Background Dietary lignans belong to the group of phytoestrogens together with coumestans, stilbenes and isoflavones, and themselves do not exhibit oestrogen-like properties. Nonetheless, the gut microbiota converts them into enterolignans, which show chemical similarity to the human oestrogen molecule. One of the richest dietary sources of lignans are oilseeds, including flaxseed. The aim of this pilot study was to determine the concentration of the main dietary lignans in an oilseed mix, and explore the gut microbiota-dependent production of enterolignans for oestrogen substitution in young and premenopausal women. The oilseed mix was fermented in a pH-controlled batch culture system inoculated with women’s faecal samples. The lignan content and enterolignan production were measured by ultra‐high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS), and the faecal-derived microbial communities were profiled by 16S rRNA gene-based next-generation sequencing. Results In vitro batch culture fermentation of faecal samples inoculated with oilseed mix for 24 h resulted in a substantial increase in enterolactone production in younger women and an increase in enterodiol in the premenopausal group. As for the gut microbiota, different baseline profiles were observed as well as different temporal dynamics, mainly related to Clostridiaceae, and Klebsiella and Collinsella spp. Conclusions Despite the small sample size, our pilot study revealed that lignan-rich oilseeds could strongly influence the faecal microbiota of both younger and premenopausal females, leading to a different enterolignan profile being produced. Further studies in larger cohorts are needed to evaluate the long-term effects of lignan-rich diets on the gut microbiota and find out how enterolactone-producing bacterial species could be increased. Diets rich in lignans could potentially serve as a safe supplement of oestrogen analogues to meet the cellular needs of endogenous oestrogen and deliver numerous health benefits, provided that the premenopausal woman microbiota is capable of converting dietary precursors into enterolignans.
- Published
- 2020
- Full Text
- View/download PDF
3. A pilot study to assess the effect of a fibre and mineral formulation on satiety and satiation when taken as part of a calorie restriction diet in overweight and obese women
- Author
-
Enver Keleszade, Tamara Willner, Michael Patterson, Steven Trangmar, Sofia Kolida, and Adele Costabile
- Subjects
Obesity ,Weight loss ,Gut microbiome ,Dysbiosis ,Cravings ,Mood ,Nutrition. Foods and food supply ,TX341-641 - Abstract
An approach that combines weight loss with additional health benefits is very desirable. Glucomannan is a dietary fibre that expands in the stomach, creating the feeling of fullness, while chromium can regulate insulin response. Oligofructose is a non-digestible prebiotic fibre with well-established bifidogenic properties that may also have a role in regulating satiety and systemic inflammation. The aim of this 4-week pilot human intervention was to investigate the effect of agglomerated glucomannan, oligofructose and chromium, as part of a calorie restricted diet plan, on weight loss, satiety, satiation, mood and gut microbiota in 12 females (18–65 years, BMI 25–35 kg/m2). Significant reductions were observed in the anthropometric parameters and systolic blood pressure at the end of trial along with a positive impact on gut microbiota and food cravings. This pilot study suggests that this dietary combination, within an energy restricted, diet may be beneficial in managing obesity related health outcomes.
- Published
- 2020
- Full Text
- View/download PDF
4. An In Vitro Pilot Fermentation Study on the Impact of Chlorella pyrenoidosa on Gut Microbiome Composition and Metabolites in Healthy and Coeliac Subjects
- Author
-
Carmen van der Linde, Monica Barone, Silvia Turroni, Patrizia Brigidi, Enver Keleszade, Jonathan R. Swann, and Adele Costabile
- Subjects
C. pyrenoidosa ,in vitro gut model ,gut microbiome ,metabolism ,Organic chemistry ,QD241-441 - Abstract
The response of a coeliac and a healthy gut microbiota to the green algae Chlorella pyrenoidosa was evaluated using an in vitro continuous, pH controlled, gut model system, which simulated the human colon. The effect of C. pyrenoidosa on the microbial structure was determined by 16S rRNA gene sequencing and inferred metagenomics, whereas the metabolic activitywas determined by1H-nuclear magnetic resonancespectroscopic analysis. The addition of C. pyrenoidosa significantly increased the abundance of the genera Prevotella, Ruminococcus and Faecalibacterium in the healthy donor, while an increase in Faecalibacterium, Bifidobacterium and Megasphaera and a decrease in Enterobacteriaceae were observed in the coeliac donor. C. pyrenoidosa also altered several microbial pathways including those involved in short-chain fatty acid (SCFA) production. At the metabolic level, a significant increase from baseline was seen in butyrate and propionate (p < 0.0001) in the healthy donor, especially in vessels 2 and 3. While acetate was significantly higher in the healthy donor at baseline in vessel 3 (p < 0.001) compared to the coeliac donor, this was markedly decreased after in vitro fermentation with C. pyrenoidosa. This is the first in vitro fermentation study of C. pyrenoidosa and human gut microbiota, however, further in vivo studies are needed to prove its efficacy.
- Published
- 2021
- Full Text
- View/download PDF
5. Clinical Efficacy of Brown Seaweeds Ascophyllum nodosum and Fucus vesiculosus in the Prevention or Delay Progression of the Metabolic Syndrome: A Review of Clinical Trials
- Author
-
Enver Keleszade, Michael Patterson, Steven Trangmar, Kieran J. Guinan, and Adele Costabile
- Subjects
seaweeds ,Ascophyllum nodosum ,Fucus vesiculosus ,metabolic syndrome ,Organic chemistry ,QD241-441 - Abstract
Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans. This review intends to provide an overview of the potential of brown seaweed extracts Ascophyllum nodosum and Fucus vesiculosus for the management and prevention of MetS and related conditions, based on the available evidence obtained from clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
6. Comparative Evaluation of the Antimicrobial and Mucus Induction Properties of Selected Bacillus Strains against Enterotoxigenic Escherichia coli
- Author
-
Natalia Bravo Santano, Erik Juncker Boll, Lena Catrine Capern, Tomasz Maciej Cieplak, Enver Keleszade, Michal Letek, and Adele Costabile
- Subjects
Escherichia coli ,adhesion ,goblet-cell-derived mucins ,probiotics ,Bacillus ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Probiotics have been shown to bind to host receptors, which are important for pathogen adhesion and induce the host’s production of defence factors. They can activate the goblet-cell-derived production of mucins, a major component of the mucus layer and a physical barrier participating in limiting the proximity of microorganisms to the epithelial layer. In the last decade, Bacillus spp. strains have gained interest in human and animal health due to their tolerance and stability under gastrointestinal tract conditions. Moreover, Bacillus spp. strains can also produce various antimicrobial peptides that can support their use as commercial probiotic supplements and functional foods. The present study aimed to evaluate and determine the ability of selected Bacillus spp. strains to inhibit the growth of enterotoxigenic Escherichia coli (ETEC) F4 and to reduce binding of ETEC F4 to HT29-16E (mucus-secreting and goblet-like) human intestinal cells. Moreover, mucus production in the HT29 cells in the presence of the Bacillus spp. strains was quantified by ELISA. Bacillus spp. strains (CHCC 15076, CHCC 15516, CHCC 15541, and CHCC 16872) significantly inhibited the growth of ETEC F4. Moreover, the ability of the probiotic Bacillus spp. strains to stimulate mucin release was highly strain dependent. The treatment with Bacillus subtilis CHCC 15541 resulted in a significant increase of both MUC2 and MUC3 in HT29-16E cells. Therefore, this strain could be an up-and-coming candidate for developing commercial probiotic supplements to prevent infections caused by ETEC F4 and, potentially, other pathogens.
- Published
- 2020
- Full Text
- View/download PDF
7. An In Vitro Pilot Fermentation Study on the Impact of Chlorella pyrenoidosa on Gut Microbiome Composition and Metabolites in Healthy and Coeliac Subjects
- Author
-
Patrizia Brigidi, Carmen van der Linde, Silvia Turroni, Enver Keleszade, Monica Barone, Jonathan R. Swann, Adele Costabile, van der Linde, Carmen, Barone, Monica, Turroni, Silvia, Brigidi, Patrizia, Keleszade, Enver, Swann, Jonathan R, and Costabile, Adele
- Subjects
Pharmaceutical Science ,gut microbiome ,Chlorella ,Butyrate ,Gut flora ,Article ,Analytical Chemistry ,03 medical and health sciences ,in vitro gut model ,QD241-441 ,Enterobacteriaceae ,RNA, Ribosomal, 16S ,Drug Discovery ,Megasphaera ,Prevotella ,Chlorella pyrenoidosa ,C. pyrenoidosa ,Food science ,Physical and Theoretical Chemistry ,030304 developmental biology ,Bifidobacterium ,0303 health sciences ,biology ,030306 microbiology ,Chemistry ,Ruminococcus ,Organic Chemistry ,biology.organism_classification ,Gastrointestinal Microbiome ,Chemistry (miscellaneous) ,Fermentation ,Molecular Medicine ,metabolism - Abstract
The response of a coeliac and a healthy gut microbiota to the green algae Chlorella pyrenoidosa was evaluated using an in vitro continuous, pH controlled, gut model system, which simulated the human colon. The effect of C. pyrenoidosa on the microbial structure was determined by 16S rRNA gene sequencing and inferred metagenomics, whereas the metabolic activitywas determined by1H-nuclear magnetic resonancespectroscopic analysis. The addition of C. pyrenoidosa significantly increased the abundance of the genera Prevotella, Ruminococcus and Faecalibacterium in the healthy donor, while an increase in Faecalibacterium, Bifidobacterium and Megasphaera and a decrease in Enterobacteriaceae were observed in the coeliac donor. C. pyrenoidosaalso altered several microbial pathways including those involved in short-chain fatty acid (SCFA) production. At the metabolic level, a significant increase from baseline was seen in butyrate and propionate (P <, 0.0001) in the healthy donor, especially in vessels 2 and 3. While acetate was significantly higher in the healthy donor at baseline in vessel 3 (P <, 0.001) compared to the coeliac donor, this was markedly decreased after in vitro fermentation with C. pyrenoidosa. This is the first in vitro fermentation study of C. pyrenoidosa and human gut microbiota, however, further in vivo studies are needed to prove its efficacy.
- Published
- 2021
- Full Text
- View/download PDF
8. Clinical Efficacy of Brown Seaweeds Ascophyllum nodosum and Fucus vesiculosus in the Prevention or Delay Progression of the Metabolic Syndrome: A Review of Clinical Trials
- Author
-
Kieran J. Guinan, Enver Keleszade, Adele Costabile, Michael Patterson, and Steven J. Trangmar
- Subjects
Ascophyllum nodosum ,Pharmaceutical Science ,Fucus vesiculosus ,030209 endocrinology & metabolism ,Review ,Analytical Chemistry ,lcsh:QD241-441 ,03 medical and health sciences ,0302 clinical medicine ,Nutraceutical ,lcsh:Organic chemistry ,Drug Discovery ,medicine ,Humans ,Glycoside Hydrolase Inhibitors ,Clinical efficacy ,Food science ,Physical and Theoretical Chemistry ,Abdominal obesity ,Ascophyllum ,030304 developmental biology ,Metabolic Syndrome ,0303 health sciences ,Clinical Trials as Topic ,biology ,Plant Extracts ,Organic Chemistry ,biology.organism_classification ,medicine.disease ,Seaweed ,Clinical trial ,seaweeds ,Chemistry (miscellaneous) ,Brown seaweed ,Fucus ,Molecular Medicine ,medicine.symptom ,Metabolic syndrome - Abstract
Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans. This review intends to provide an overview of the potential of brown seaweed extracts Ascophyllum nodosum and Fucus vesiculosus for the management and prevention of MetS and related conditions, based on the available evidence obtained from clinical trials.
- Published
- 2021
9. Impact of lignans in oilseed mix on gut microbiome composition and enterolignan production in younger healthy and premenopausal women: an in vitro pilot study
- Author
-
Silvia Turroni, Anna Kreimes, Enver Keleszade, Adele Costabile, Patrizia Brigidi, Giulia Corona, Monica Barone, Corona G., Kreimes A., Barone M., Turroni S., Brigidi P., Keleszade E., and Costabile A.
- Subjects
Enterodiol ,Lignan ,Enterolignans ,lcsh:QR1-502 ,Bioengineering ,Pilot Projects ,Gut flora ,Enterolignan ,Plant Oil ,Applied Microbiology and Biotechnology ,lcsh:Microbiology ,Lignans ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Enterolactone ,Humans ,Plant Oils ,Pilot Project ,Clostridiaceae ,Food science ,030304 developmental biology ,0303 health sciences ,Gut microbiome ,biology ,Research ,Case-control study ,Isoflavones ,biology.organism_classification ,Flaxseed ,Gastrointestinal Microbiome ,Metabolism ,chemistry ,Premenopause ,030220 oncology & carcinogenesis ,Case-Control Studies ,Phytoestrogens ,Female ,Case-Control Studie ,Human ,Biotechnology - Abstract
Background Dietary lignans belong to the group of phytoestrogens together with coumestans, stilbenes and isoflavones, and themselves do not exhibit oestrogen-like properties. Nonetheless, the gut microbiota converts them into enterolignans, which show chemical similarity to the human oestrogen molecule. One of the richest dietary sources of lignans are oilseeds, including flaxseed. The aim of this pilot study was to determine the concentration of the main dietary lignans in an oilseed mix, and explore the gut microbiota-dependent production of enterolignans for oestrogen substitution in young and premenopausal women. The oilseed mix was fermented in a pH-controlled batch culture system inoculated with women’s faecal samples. The lignan content and enterolignan production were measured by ultra‐high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS), and the faecal-derived microbial communities were profiled by 16S rRNA gene-based next-generation sequencing. Results In vitro batch culture fermentation of faecal samples inoculated with oilseed mix for 24 h resulted in a substantial increase in enterolactone production in younger women and an increase in enterodiol in the premenopausal group. As for the gut microbiota, different baseline profiles were observed as well as different temporal dynamics, mainly related to Clostridiaceae, and Klebsiella and Collinsella spp. Conclusions Despite the small sample size, our pilot study revealed that lignan-rich oilseeds could strongly influence the faecal microbiota of both younger and premenopausal females, leading to a different enterolignan profile being produced. Further studies in larger cohorts are needed to evaluate the long-term effects of lignan-rich diets on the gut microbiota and find out how enterolactone-producing bacterial species could be increased. Diets rich in lignans could potentially serve as a safe supplement of oestrogen analogues to meet the cellular needs of endogenous oestrogen and deliver numerous health benefits, provided that the premenopausal woman microbiota is capable of converting dietary precursors into enterolignans.
- Published
- 2020
10. Impact of lignans in oilseed mix on gut microbiome composition and enterolignan production in younger healthy and premenopausal women: an in vitro study
- Author
-
Giulia Corona, Anna Kreimes, Monica Barone, Silvia Turroni, Patrizia Brigidi, Enver Keleszade, and Adele Costabile
- Abstract
BackgroundDietary lignans belong to the group of phytoestrogens together with coumestans, stilbenes and isoflavones, and themselves do not exhibit oestrogen-like properties. Nonetheless, the gut microbiota converts them into enterolignans, which show chemical similarity to the human oestrogen molecule. One of the richest dietary sources of lignans are oilseeds, including flaxseed. The aim of this study was to determine the concentration of the main dietary lignans in an oilseed mix, and evaluate the gut microbiota-dependent production of enterolignans for oestrogen substitution in young and premenopausal women. The oilseed mix was fermented in a pH-controlled batch culture system inoculated with women’s faecal samples. The lignan content and enterolignan production were measured by ultra‐high-performance liquid chromatography – tandem mass spectrometry (UHPLC-MS/MS), and the gut-derived microbial communities were profiled by 16S rRNA gene-based next-generation sequencing.ResultsIn vitro batch culture fermentation of faecal samples inoculated with oilseed mix for 24 h resulted in a substantial increase in enterolactone production in younger women and an increase in enterodiol in the premenopausal group. As for the gut microbiota, different baseline profiles were observed as well as different temporal dynamics, mainly related to Clostridiaceae, and Klebsiella and Collinsella spp. ConclusionsDespite the small sample size, our results revealed that lignan-rich oilseeds have a strong influence on the faecal microbiota of both younger and premenopausal females, leading to a different enterolignan profile being produced. More studies are needed to evaluate the long-term effects of lignan-rich diets on the gut microbiota and find out how enterolactone-producing bacterial species could be increased. Diets rich in lignans could potentially serve as a safe supplement of oestrogen analogues to satisfy cellular needs for endogenous oestrogen and deliver numerous health benefits, provided that the premenopausal woman microbiota is capable of converting dietary precursors to enterolignans.
- Published
- 2019
11. Comparative Evaluation of the Antimicrobial and Mucus Induction Properties of Selected Bacillus Strains against Enterotoxigenic Escherichia coli
- Author
-
Lena Catrine Capern, Michal Letek, Tomasz Maciej Cieplak, Adele Costabile, Enver Keleszade, Erik Juncker Boll, and Natalia Bravo Santano
- Subjects
0301 basic medicine ,Microbiology (medical) ,030106 microbiology ,Antimicrobial peptides ,goblet-cell-derived mucins ,Bacillus ,Bacillus subtilis ,medicine.disease_cause ,Biochemistry ,Microbiology ,law.invention ,03 medical and health sciences ,Probiotic ,law ,Enterotoxigenic Escherichia coli ,Escherichia coli ,medicine ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,biology ,Communication ,lcsh:RM1-950 ,fungi ,biology.organism_classification ,Antimicrobial ,Mucus ,adhesion ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,Infectious Diseases ,probiotics - Abstract
Probiotics have been shown to bind to host receptors, which are important for pathogen adhesion and induce the host’s production of defence factors. They can activate the goblet-cell-derived production of mucins, a major component of the mucus layer and a physical barrier participating in limiting the proximity of microorganisms to the epithelial layer. In the last decade, Bacillus spp. strains have gained interest in human and animal health due to their tolerance and stability under gastrointestinal tract conditions. Moreover, Bacillus spp. strains can also produce various antimicrobial peptides that can support their use as commercial probiotic supplements and functional foods. The present study aimed to evaluate and determine the ability of selected Bacillus spp. strains to inhibit the growth of enterotoxigenic Escherichia coli (ETEC) F4 and to reduce binding of ETEC F4 to HT29-16E (mucus-secreting and goblet-like) human intestinal cells. Moreover, mucus production in the HT29 cells in the presence of the Bacillus spp. strains was quantified by ELISA. Bacillus spp. strains (CHCC 15076, CHCC 15516, CHCC 15541, and CHCC 16872) significantly inhibited the growth of ETEC F4. Moreover, the ability of the probiotic Bacillus spp. strains to stimulate mucin release was highly strain dependent. The treatment with Bacillus subtilis CHCC 15541 resulted in a significant increase of both MUC2 and MUC3 in HT29-16E cells. Therefore, this strain could be an up-and-coming candidate for developing commercial probiotic supplements to prevent infections caused by ETEC F4 and, potentially, other pathogens.
- Published
- 2020
12. A pilot study to assess the effect of a fibre and mineral formulation on satiety and satiation when taken as part of a calorie restriction diet in overweight and obese women
- Author
-
Sofia Kolida, Steven J. Trangmar, Adele Costabile, Enver Keleszade, Tamara Willner, and Michael Patterson
- Subjects
0301 basic medicine ,Weight loss ,Cravings ,medicine.medical_treatment ,Calorie restriction ,Medicine (miscellaneous) ,Glucomannan ,Physiology ,Gut flora ,Overweight ,03 medical and health sciences ,chemistry.chemical_compound ,0404 agricultural biotechnology ,Mood ,Medicine ,TX341-641 ,Obesity ,Gut microbiome ,030109 nutrition & dietetics ,Nutrition and Dietetics ,biology ,Nutrition. Foods and food supply ,business.industry ,Prebiotic ,04 agricultural and veterinary sciences ,biology.organism_classification ,medicine.disease ,040401 food science ,Blood pressure ,chemistry ,Dysbiosis ,medicine.symptom ,business ,Food Science - Abstract
An approach that combines weight loss with additional health benefits is very desirable. Glucomannan is a dietary fibre that expands in the stomach, creating the feeling of fullness, while chromium can regulate insulin response. Oligofructose is a non-digestible prebiotic fibre with well-established bifidogenic properties that may also have a role in regulating satiety and systemic inflammation. The aim of this 4-week pilot human intervention was to investigate the effect of agglomerated glucomannan, oligofructose and chromium, as part of a calorie restricted diet plan, on weight loss, satiety, satiation, mood and gut microbiota in 12 females (18–65 years, BMI 25–35 kg/m2). Significant reductions were observed in the anthropometric parameters and systolic blood pressure at the end of trial along with a positive impact on gut microbiota and food cravings. This pilot study suggests that this dietary combination, within an energy restricted, diet may be beneficial in managing obesity related health outcomes.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.